PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$37.18 MCurrent assets$807.15 MLiabilities$44.00 MAssets$885.54 MNon-current liabilities$6.82 MEquity$841.54 MGross equity(calculated)$1.15 BNon-current assets$78.40 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSCash and cash equivalentsMarketable securitiesReceivable from collaboration partnerPrepaid expenses and other current assetsContract assetMarketable securities - noncurrentOperating lease right-of-use assetProperty and equipment, netOther non-current assetsRestricted cash - noncurrentAccrued expenses and other payablesDeferred revenueAccounts payableOperating lease liabilityOperating lease liability - noncurrentAdditional paid-in capitalCommon stock, $0.00001 par value, 180,000,000 shares authorized; 64,672,032 and 62,577,897 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive (loss) incomeAccrued expenses and other payablesAccrued expenses and other payables$21.67 MCurrent liabilitiesCurrent liabilities$37.18 MCurrent assetsCurrent assets$807.15 MDeferred revenueDeferred revenue$9.66 MCash and cash equivalentsCash and cash equivalents$420.08 MAccounts payableAccounts payable$3.46 MLiabilitiesLiabilities$44.00 MOperating lease liabilityOperating lease liability$2.40 MAssetsAssets$885.54 MNon-current liabilitiesNon-current liabilities$6.82 MEquityEquity$841.54 MOperating lease liability - noncurrentOperating lease liability - noncurrent$6.82 MGross equity (calculated)Gross equity(calculated)$1.15 BMarketable securitiesMarketable securities$362.50 MReceivable from collaboration partnerReceivable from collaboration partner$13.42 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$7.79 MContract assetContract asset$3.37 MAdditional paid-in capitalAdditional paid-in capital$1.15 BMarketable securities - noncurrentMarketable securities - noncurrent$66.88 MOperating lease right-of-use assetOperating lease right-of-use asset$6.95 MNon-current assetsNon-current assets$78.40 MProperty and equipment, netProperty and equipment, net$3.46 MOther non-current assetsOther non-current assets$832.00 KRestricted cash - noncurrentRestricted cash - noncurrent$287.00 KCommon stock, $0.00001 par value, 180,000,000 shares authorized; 64,672,032 and 62,577,897 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$1.00 KAccumulated deficitAccumulated deficit−$304.04 MAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$828.00 K
Chart details

PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
885,544,000 US dollars
Current assets
807,148,000 US dollars
Non-current assets
78,396,000 US dollars
Liabilities
44,001,000 US dollars
Current liabilities
37,181,000 US dollars
Non-current liabilities
6,820,000 US dollars
Equity
841,543,000 US dollars
Cash and cash equivalents
420,078,000 US dollars
Marketable securities
362,498,000 US dollars
Receivable from collaboration partner
13,416,000 US dollars
Prepaid expenses and other current assets
7,790,000 US dollars
Contract asset
3,366,000 US dollars
Marketable securities - noncurrent
66,875,000 US dollars
Operating lease right-of-use asset
6,946,000 US dollars
Property and equipment, net
3,456,000 US dollars
Other non-current assets
832,000 US dollars
Restricted cash - noncurrent
287,000 US dollars
Accrued expenses and other payables
21,667,000 US dollars
Deferred revenue
9,659,000 US dollars
Accounts payable
3,459,000 US dollars
Operating lease liability
2,396,000 US dollars
Operating lease liability - noncurrent
6,820,000 US dollars
Additional paid-in capital
1,146,409,000 US dollars
Common stock, $0.00001 par value, 180,000,000 shares authorized; 64,672,032 and 62,577,897 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
1,000 US dollars
Accumulated deficit
negative 304,039,000 US dollars
Accumulated other comprehensive (loss) income
negative 828,000 US dollars
Gross equity (calculated)
1,146,410,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
PROTAGONIST THERAPEUTICS, INC. (PTGX) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!